- World rank, all time
- #5,659 of 42,892
- Rank in Italy
- #187 of 969
- Research works
- 261 ▲ 18% vs 2013–17
- Citations
- 13k 48.9 per fractional work
- Top-10% rate
- 10.8% record average 16.5%
- Open access
- 41% world 28%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Economics, Econometrics and Finance, 10.2×. Every wedge is a field page.
- Economics, Econometrics and Finance 10.2×
- Immunology and Microbiology 4.2×
- Medicine 2.4×
- Biochemistry, Genetics and Molecular Biology 1.7×
- Agricultural and Biological Sciences 1.3×
- Health Professions 0.8×
- Pharmacology, Toxicology and Pharmaceutics 0.6×
- Mathematics 0.5×
- Decision Sciences 0.5×
- Social Sciences 0.3×
- Neuroscience 0.3×
- Environmental Science 0.2×
- Business, Management and Accounting 0.2×
- Earth and Planetary Sciences 0.1×
- Computer Science 0.1×
- Arts and Humanities 0.1×
- Engineering 0.1×
Who are the top researchers at Roche (Italy)?
Ranked on the composite score, Luciano Adorini and Giovanni Giuliani lead among researchers whose main affiliation is Roche (Italy).
- 1 Luciano Adorini Italy · #78,841 worldwide 306 citations · 52 works
- 2 Giovanni Giuliani Italy · #1,231,974 worldwide 17 citations · 16 works
Which keywords describe research at Roche (Italy)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Quality of Life, Economic Evaluation, Cost-effectiveness Analysis, Health Utility Measures, Diabetic Retinopathy, Macular Degeneration, Lymphoma and Clinical Trials.
- PET Imaging
- Immunosuppressive Therapy
- Cancer Genomics
- Chemotherapy
- Retinal Pigment Epithelium
- Cost of Care
- SMN1
- Immunogenicity
- Oxidative Stress
- Rituximab
- Lymphoma
- Clinical Trials
- Diabetic Retinopathy
- Health Utility Measures
- Cost-effectiveness Analysis
- Quality of Life
- Economic Evaluation
- Epidemiology
- Macular Degeneration
- Immunotherapy
- Targeted Therapy
- Prognostic Factors
- Biosimilars
- Inflammation
- Spinal Muscular Atrophy
- Financial Toxicity
- Vascular Endothelial Growth Factor
- CAR T Cells
- Chimeric Antigen Receptor
- Mutational Signatures
- Prophylaxis
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 31 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 31 words, with their numbers
- Quality of Life5▲ 10×4 topics
- Cost-effectiveness Analysis5▲ 165×1 topic
- Economic Evaluation5▲ 117×2 topics
- Health Utility Measures5▲ 165×1 topic
- Epidemiology2▲ 1.64×7 topics
- Diabetic Retinopathy2▲ 61×2 topics
- Macular Degeneration2▲ 50×2 topics
- Clinical Trials2▲ 8.5×7 topics
- Immunotherapy2▲ 7.9×4 topics
- Lymphoma2▲ 36×2 topics
- Targeted Therapy2▲ 25×3 topics
- Rituximab2▲ 35×3 topics
- Prognostic Factors2▲ 12×5 topics
- Oxidative Stress2▲ 3.0×3 topics
- Biosimilars1▲ 193×1 topic
- Immunogenicity1▲ 89×1 topic
- Inflammation1▲ 1.89×2 topics
- SMN11▲ 178×1 topic
- Spinal Muscular Atrophy1▲ 178×1 topic
- Cost of Care1▲ 119×1 topic
- Financial Toxicity1▲ 119×1 topic
- Retinal Pigment Epithelium1▲ 71×1 topic
- Vascular Endothelial Growth Factor1▲ 44×1 topic
- Chemotherapy1▲ 4.7×10 topics
- CAR T Cells1▲ 43×1 topic
- Cancer Genomics1▲ 43×1 topic
- Chimeric Antigen Receptor1▲ 43×1 topic
- Immunosuppressive Therapy1▲ 16×2 topics
- Mutational Signatures1▲ 43×1 topic
- PET Imaging1▲ 17×2 topics
- Prophylaxis1▲ 22×2 topics
Which research topics does Roche (Italy) publish most on?
By volume in 2022–2025: Health Systems, Economic Evaluations, Quality of Life, Biosimilars and Bioanalytical Methods, Neurogenetic and Muscular Disorders Research and Retinal Diseases and Treatments.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 5 works
- 2 Biosimilars and Bioanalytical Methods Immunology 1 works
- 3 Neurogenetic and Muscular Disorders Research Genetics 1 works
- 4 Retinal Diseases and Treatments Ophthalmology 1 works
- 5 Economic and Financial Impacts of Cancer Economics and Econometrics 1 works
- 6 Cancer Genomics and Diagnostics Cancer Research 1 works
- 7 CAR-T cell therapy research Oncology 1 works
- 8 Hemophilia Treatment and Research Hematology 1 works
- 9 Lymphoma Diagnosis and Treatment Pathology and Forensic Medicine 1 works
- 10 Retinal Imaging and Analysis Radiology, Nuclear Medicine and Imaging 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Roche (Italy)'s research output changed?
Output in 2018–2022 was 18% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Milan
- University of Milan
- Politecnico di Milano
- Università Cattolica del Sacro Cuore
- University of Milano-Bicocca
- Vita-Salute San Raffaele University
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
- Fondazione IRCCS Istituto Nazionale dei Tumori
- Mario Negri Institute for Pharmacological Research
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.